Sesen Bio, Inc. SESN
We take great care to ensure that the data presented and summarized in this overview for Sesen Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SESN
View allLatest Institutional Activity in SESN
Top Purchases
Top Sells
About SESN
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SESN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2023
|
Chidozie Ugwumba Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,215,877
+50.0%
|
-
|
|
Mar 07
2023
|
Michael Torok Director |
BUY
Grant, award, or other acquisition
|
Indirect |
369,991
+50.0%
|
-
|
|
Mar 07
2023
|
Michael Torok Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,250
+50.0%
|
-
|
|
Mar 07
2023
|
Michael Klichinsky Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
484,347
+50.0%
|
-
|
|
Mar 07
2023
|
Regina Hodits Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,297,546
+50.0%
|
-
|
|
Mar 07
2023
|
Briggs Morrison Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,175
+50.0%
|
-
|
|
Mar 07
2023
|
Sanford S Zweifach Director |
BUY
Grant, award, or other acquisition
|
Direct |
413
+50.0%
|
-
|
|
Mar 02
2023
|
Elly Ryu Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
17,289
-10.42%
|
$0
$0.59 P/Share
|
|
Mar 02
2023
|
Glen C Mac Donald Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
170,372
-16.74%
|
$0
$0.59 P/Share
|
|
Mar 02
2023
|
Glen C Mac Donald Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
286,292
+25.6%
|
$0
$0.59 P/Share
|
|
Mar 02
2023
|
Mark Sullivan General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
219,218
-21.14%
|
$0
$0.59 P/Share
|
|
Mar 02
2023
|
Mark Sullivan General Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
298,175
+26.81%
|
$0
$0.59 P/Share
|
|
Mar 02
2023
|
Monica Forbes Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
345,849
-22.15%
|
$0
$0.59 P/Share
|
|
Mar 02
2023
|
Monica Forbes Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
371,125
+24.98%
|
$0
$0.59 P/Share
|
|
Mar 02
2023
|
Thomas R Cannell President and CEO |
SELL
Open market or private sale
|
Direct |
487,487
-33.53%
|
$0
$0.59 P/Share
|
|
Mar 02
2023
|
Thomas R Cannell President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
606,800
+38.95%
|
$0
$0.59 P/Share
|
|
Feb 21
2023
|
Thomas R Cannell President and CEO |
SELL
Open market or private sale
|
Direct |
53,727
-8.85%
|
$0
$0.59 P/Share
|
|
Feb 21
2023
|
Elly Ryu Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
7,159
-4.14%
|
$0
$0.59 P/Share
|
|
Feb 21
2023
|
Mark Sullivan General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
39,831
-11.73%
|
$0
$0.59 P/Share
|
|
Feb 21
2023
|
Glen C Mac Donald Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
25,927
-8.39%
|
$0
$0.59 P/Share
|